Letter: real-world use of terlipressin in patients with hepatorenal syndrome

Affiliations

Comment

Fangbin Weng. Aliment Pharmacol Ther. 2021 Aug.

. 2021 Aug;54(3):349.

doi: 10.1111/apt.16449.

No abstract available

Comment in

Letter: real-world use of terlipressin in patients with the hepatorenal syndrome-authors' reply.
Allegretti AS, Jamil K, Moore K. Allegretti AS, et al. Aliment Pharmacol Ther. 2021 Aug;54(3):350-351. doi: 10.1111/apt.16486. Aliment Pharmacol Ther. 2021. PMID: 34236097 No abstract available.

Real-world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome.
Moore K, Jamil K, Verleger K, Luo L, Kebede N, Heisen M, Corman S, Leonardi R, Bakker R, Maï C, Shamseddine N, Huang X, Allegretti AS. Moore K, et al. Aliment Pharmacol Ther. 2020 Jul;52(2):351-358. doi: 10.1111/apt.15836. Epub 2020 Jun 4. Aliment Pharmacol Ther. 2020. PMID: 32495956 Free PMC article.

1. Moore K, Jamil K, Verleger K, et al. Real-world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome. Aliment Pharmacol Ther. 2020;52:351-358.
1. Angeli P, Garcia-Tsao G, Nadim MK, Parikh CR. News in pathophysiology, definition and classification of hepatorenal syndrome: a step beyond the International Club of Ascites (ICA) consensus document. J Hepatol. 2019;71:811-822.
1. Piano S, Schmidt HH, Ariza X, et al. Association between grade of acute on chronic liver failure and response to terlipressin and albumin in patients with hepatorenal syndrome. Clin Gastroenterol Hepatol. 2018;16:1792-1800.e1793.
1. Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology. 2002;122:923-930.
1. Fernández J, Clària J, Amorós A, et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis. Gastroenterology. 2019;157:149-162.